Valuation dashboard for Orchestra BioMed Holdings, Inc. (OBIO) with P/E N/A, P/B 11.92, EV/EBITDA -5.85 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures.
Analysis Summary
Orchestra BioMed Holdings, Inc. reported revenue of $33.5M in the most recent fiscal year, growing at a 5-year CAGR of 42.5%.
Trailing-twelve-month margins: gross margin 99.3%, operating margin -181.4%, net margin -184.6%.
At the current price of $6.01, OBIO has negative trailing earnings (P/E not meaningful) and an ROE of -125.93%. Market capitalisation stands at $360M.
Balance sheet quality for OBIO: current ratio of 6.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 11.92 |
| EV / EBITDA | -5.85 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-5.61 |
| vs Current Price | -193.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| OBIO | Orchestra BioMed Holdings, Inc. | $360M | 11.92 | -125.9% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $6.01 |
| Market Cap | $360M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -125.93% |
| Return on Invested Capital | -56.28% |
| Return on Assets | -51.02% |
| Gross Margin | 99.32% |
| Operating Margin | -181.36% |
| Net Margin | -184.60% |
Related companies: AVTX · CRBU · ENTA · EPRX · IVA · IVVD · PRLD
Explore sector: Healthcare · Biotechnology
More sections of OBIO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks